1Sun J,Yang Q,Lu Z,et al.Distribution of lymphoid neoplasms in China:analysis of 4,638 cases according to the World Health Organization classification[J].Am J Clin Pathol,2012,138(3):429-434.
2Swerdlow SH.WHO classification of tumours of haematopoietic and lymphoid tissues.4th edition.IARC Press,Lyon,France;2008.
3Vose J,Armitage J,Weisenburger D.International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes[J].J Clin Oncol,2008,26(25):4124-4130.
4NCCN Clinical Practice Guidelines in Oncology.NonHodgkin’s lymphoma,V.2.2015.Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.Accessed March 23,2015.
5Yang L,Liu H,Xu XH,et al.Retrospective study of modified SMILE chemotherapy for advanced-stage,relapsed,or refractory extranodal natural killer(NK)/T cell lymphoma,nasal type[J].Med Oncol,2013,30(4):720.
6Gu R,Liu T,Zhu X,et al.Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide(epidaza),a new benzamide class of selective histone deacetylase inhibitor,in human plasma and its clinical application[J].J Chromatogr B Analyt Technol Biomed Life Sci,2015,1000:181-186.
7Marquard L,Poulsen CB,Gjerdrum LM,et al.Histone deacetylase 1,2,6 and acetylated histone H4 in B-and Tcell lymphomas[J].Histopathology,2009,54(6):688-98.
8Ning ZQ.Li ZB.Newman MJ.et a1.Chidamide(CS055/HBI-8000):a new hismne deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity[J].Cancer Chemother Pharmacol,2012,69(4):901-909.
9Shi Y,Dong M,Hong X,et al.Results from a multicenter,open-label,pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J].Ann Oncol,2015,26(8):1766-1771.
